<DOC>
	<DOCNO>NCT01489124</DOCNO>
	<brief_summary>This prospective , randomize crossover design assess pharmacokinetic pharmacodynamics three regimen . - 0.5-hr infusion imipenem 0.5 g every 6 hr - 2-hr infusion imipenem 0.5 g every 6 hr - 2-hr infusion imipenem 1 g every 6 hr Clinical laboratory data Age , Sex , Body weight , CBC , Electrolyte , Vital sign , APACHE II score , BUN , Cr , Sample Blood culture collect . Nine patient enrol study . After completion imipenem therapy 3 day study , patient receive sensitive antibiotic eradicate bacterial infection . Blood sample ( approximately 3 ml ) obtain direct venepuncture follow time : 0 , 0.5 , 1 , 2 , 3 , 4 , 5 6 4th dose imipenem . Concentration imipenem plasma measure HPLC method . Then , data simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response ) .</brief_summary>
	<brief_title>The Population Pharmacokinetics Imipenem Patients With Ventilator-associated Pneumonia</brief_title>
	<detailed_description>Introduction : Ventilator-associated pneumonia ( VAP ) common cause nosocomial infection high mortality rate . In current era increase highly resistant pathogen nosocomial infection , empirical treatment organism become difficult novel antimicrobial agent currently development activity highly resistant Gram negative bacillus infection . Imipenem , carbapenem antibiotic , β-lactam antibacterial agent broad spectrum activity Gram positive Gram negative bacteria . This agent still one commonly use antibiotic empirical therapy highly resistant nosocomial infection VAP . In common β-lactams , imipenem exhibit primarily time dependent kill increase concentration agent necessarily increase rate extent bacterial killing . Therefore , time concentration serum MIC ( T &gt; MIC ) pharmacokinetic/pharmacodynamic ( PK/PD ) index correlate efficacy . Pharmacodynamic analysis apply imipenem dosage increase likelihood optimal exposure achieve good clinical response patient VAP . Previous study perform find 2 h infusion carbapenem antibiotic give great value T &gt; MIC 0.5 h infusion . Therefore , attempt improve efficacy present β-lactam antimicrobial agent imipenem , prolonged infusion would appropriate mode administration promote maximal bactericidal effect.PK change find several hydrophilic antimicrobial agent critically ill patient . Drug disposition alter patient population compare healthy subject leading fluctuation plasma concentration . Therefore , aim study ass PD imipenem VAP patient , compare administration 0.5 h infusion 2 h infusion . Objectives : To assess pharmacokinetic pharmacodynamics three regimen . ) 0.5-hr infusion imipenem 0.5 g every 6 hr ii ) 2-hr infusion imipenem 0.5 g every 6 hr iii ) 2-hr infusion imipenem 1 g every 6 hrs Drug preparation : Imipenem reconstitute 100 ml saline solution accord manufacturer 's guideline Study design : This prospective , randomize crossover design assess Each patient receive doripenem 3 regimen consecutively : ) 0.5-hr infusion imipenem 0.5 g every 6 hr ii ) 2-hr infusion imipenem 0.5 g every 6 hr iii ) 2-hr infusion imipenem 1 g every 6 hr Nine patient enrol study . After completion imipenem therapy 3 day study , patient receive sensitive antibiotic eradicate bacterial infection . Sample collection : Blood sample ( approximately 3 ml ) obtain direct venepuncture follow time : 0 , 0.5 , 1 , 2 , 3 , 4 , 5 6 4th dose imipenem . All blood sample allow clot centrifuge 2,000g . The serum obtain store at-80°C analysis . Imipenem assay HPLC method e perform Department Medicine , Faculty Medicine . Clinical laboratory data Age , Sex , Body weight , CBC , Electrolyte , Vital sign , APACHE II score , BUN , Cr , Sample Blood culture collect . Duration study : Patients receive imipenem 3 day Pharmacokinetic pharmacodynamic analysis : Concentration imipenem plasma measure HPLC method simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response ) . Sample Size : Nine patient VAP enrol study .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<criteria>Patients age ≥ 18 year Patients intubate receive mechanical ventilation . Patients clinical suspicion VAP Gram negative bacillus infection , define new persistent infiltrate chest radiography associate least one following : purulent tracheal secretion , temperature 38.3°C high leucocyte count high 10000 cells/mm3 . Expected life expectancy ≥ 3 day Patients documented hypersensitivity imipenem carbapenems . Patients estimate creatinine clearance &lt; 60 ml/min Patients circulatory shock ( define systolic blood pressure &lt; 90 mmHg ) . Patients pregnant . Pretient receive imipenem 2 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Infection</keyword>
	<keyword>Imipenem</keyword>
	<keyword>Ventilator-Associated Pneumonia</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>